Skip to main content

Medical Data-Crunching

Jeffrey Hammerbacher has charted a course from Bear Stearns in 2005 to Facebook in 2006 to Cloudera in 2008, notes Steve Lohr in an adapted excerpt from his book Data-ism: The Revolution Transforming Decision Making, Consumer Behavior, and Almost Everything Else appearing in the New York Times. At each point along the way Hammerbacher has used math and data science, tools he's now applying to medicine.

As Lohr reports, Eric Schadt recruited Hammerbacher to Mount Sinai as part of the school's bid to make medicine more data-driven, and Hammerbacher, after dealing with a personal health crisis, was interested in pursuing such an approach.

At Mount Sinai, he is developing computational pipelines to make it, for instance, easier — and thus cheaper — to personalize cancer treatments based on the variants in a patient's tumor.

"We are trying to move medicine in the direction of climatology and physics; disciplines that are far more advanced and mature quantitatively," Schadt tells Lohr.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.